45 related articles for article (PubMed ID: 7199465)
1. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma.
Daniel P; Gaskell SJ; Bishop H; Campbell C; Nicholson RI
Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1183-9. PubMed ID: 7199465
[No Abstract] [Full Text] [Related]
2. Estrogen suppresses melatonin-enhanced hyperactivation of hamster spermatozoa.
Fujinoki M; Takei GL
J Reprod Dev; 2015; 61(4):287-95. PubMed ID: 25959801
[TBL] [Abstract][Full Text] [Related]
3. Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.
Jordan VC
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25269699
[TBL] [Abstract][Full Text] [Related]
4. Electrospray ionization mass spectrometry for analysis of low-molecular-weight anticancer drugs and their analogues.
Poon GK; Bisset GM; Mistry P
J Am Soc Mass Spectrom; 1993 Jul; 4(7):588-95. PubMed ID: 24227645
[TBL] [Abstract][Full Text] [Related]
5. Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis.
Mercer KE; Apostolov EO; Gamboa da Costa G; Yu X; Lang P; Roberts DW; Davis W; Basnakian AG; Kadlubar FF; Kadlubar SA
Int J Mol Epidemiol Genet; 2010 Jan; 1(2):92-103. PubMed ID: 21537383
[TBL] [Abstract][Full Text] [Related]
6. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
Li C; Lim SC; Kim J; Choi JS
Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):175-82. PubMed ID: 21442417
[TBL] [Abstract][Full Text] [Related]
7. Effects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptors.
de Sousa JA; Facina G; da Silva BB; Gebrim LH
Int Semin Surg Oncol; 2006 Sep; 3():29. PubMed ID: 16972993
[TBL] [Abstract][Full Text] [Related]
8. Interactions between antiretrovirals and antineoplastic drug therapy.
Antoniou T; Tseng AL
Clin Pharmacokinet; 2005; 44(2):111-45. PubMed ID: 15656694
[TBL] [Abstract][Full Text] [Related]
9. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.
MacCallum J; Cummings J; Dixon JM; Miller WR
Br J Cancer; 2000 May; 82(10):1629-35. PubMed ID: 10817496
[TBL] [Abstract][Full Text] [Related]
10. The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
Johnston SR; Riddler S; Haynes BP; A'Hern R; Smith IE; Jarman M; Dowsett M
Br J Cancer; 1997; 75(6):804-9. PubMed ID: 9062399
[TBL] [Abstract][Full Text] [Related]
11. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.
Johnston SR; Haynes BP; Sacks NP; McKinna JA; Griggs LJ; Jarman M; Baum M; Smith IE; Dowsett M
Breast Cancer Res Treat; 1993 Dec; 28(3):241-50. PubMed ID: 8018953
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.
Toko T; Shibata J; Sugimoto Y; Yamaya H; Yoshida M; Ogawa K; Matsushima E
Cancer Chemother Pharmacol; 1995; 37(1-2):7-13. PubMed ID: 7497599
[TBL] [Abstract][Full Text] [Related]
13. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.
Jordan VC
Breast Cancer Res Treat; 1983; 3 Suppl():S73-86. PubMed ID: 6423014
[TBL] [Abstract][Full Text] [Related]
14. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.
Jordan VC
Breast Cancer Res Treat; 1982; 2(2):123-38. PubMed ID: 6184101
[TBL] [Abstract][Full Text] [Related]
15. Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.
Milano G; Etienne MC; Frenay M; Khater R; Formento JL; Renee N; Moll JL; Francoual M; Berto M; Namer M
Br J Cancer; 1987 May; 55(5):509-12. PubMed ID: 3606944
[TBL] [Abstract][Full Text] [Related]
16. Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses.
Camaggi CM; Strocchi E; Canova N; Costanti B; Pannuti F
Cancer Chemother Pharmacol; 1985; 14(3):229-31. PubMed ID: 3158448
[TBL] [Abstract][Full Text] [Related]
17. Effect of continuous vs intermittent application of 3-OH-tamoxifen or tamoxifen on the proliferation of the human breast cancer cell line MCF-7 M1.
Dietel M; Löser R; Röhlke P; Jonat W; Niendorf A; Gerding D; Kohr A; Hölzel F; Arps H
J Cancer Res Clin Oncol; 1989; 115(1):36-40. PubMed ID: 2921271
[TBL] [Abstract][Full Text] [Related]
18. Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells.
Johnson MD; Westley BR; May FE
Br J Cancer; 1989 May; 59(5):727-38. PubMed ID: 2736207
[TBL] [Abstract][Full Text] [Related]
19. Biology of the protein kinase C family.
O'Brian CA; Ward NE
Cancer Metastasis Rev; 1989 Dec; 8(3):199-214. PubMed ID: 2697470
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
Buckley MM; Goa KL
Drugs; 1989 Apr; 37(4):451-90. PubMed ID: 2661195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
